Table 1 Chemotherapy regimen

Neoadjuvant chemotherapy

70

204

 PLD/Epirubicin+C, n (%)

7 (10.0%)

23 (11.3%)

 PLD/Epirubicin+C-T, n (%)

28 (40.0%)

33 (16.2%)

 PLD/Epirubicin+T, n (%)

14 (20.0%)

53 (26.0%)

 T + PLD/Epirubicin+C, n (%)

25 (38.5%)

62 (30.4%)

 others, n (%)

9 (12.9%)

33 (16.2%)

Adjuvant chemotherapy

292

647

 PLD/Epirubicin+C, n (%)

88 (30.1%)

66 (10.2%)

 PLD/Epirubicin+C + T, n (%)

22 (7.5%)

68 (10.5%)

 PLD/Epirubicin+C-T, n (%)

136 (46.6%)

255 (39.4%)

 C + PLD/Epirubicin+F, n (%)

1 (0.3%)

0 (0.0%)

 T + PLD/Epirubicin, n (%)

20 (6.9%)

198 (30.6%)

 T-PLD/Epirubicin+C, n (%)

8 (2.7%)

25 (3.9%)